Matching trials
2,411 results
- COSMOSIndependent statistical analysis of A Study in Participants With Non-cirrhotic NASH With Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05638737).
- COV002Independent statistical analysis of COV002 (NCT04400838), a randomized phase 2/3 trial investigating ChAdOx1 nCoV-19 for prevention of COVID-19 in adults, including its design, endpoints, planned statistical methods, and interpretation.
- COVID-19 PrEP HCW HCQ Study: Complete Statistical AnalysisIndependent statistical analysis of COVID-19 PrEP HCW HCQ Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04354870).
- CP-690-550 Ointment For Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of CP-690-550 Ointment For Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01246583).
- CPEX-011Independent statistical analysis of Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- CPIT001Independent statistical analysis of Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old: Complete Statistical AnalysisIndependent statistical analysis of CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients: Complete Statistical AnalysisIndependent statistical analysis of CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients: primary endpoint results, effect estimate with confidence interval,…
- CRATUSIndependent statistical analysis of AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CRC027Independent statistical analysis of Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CriSP-HSIndependent statistical analysis of Cold Stored Platelet in Hemorrhagic Shock: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04667468).
- Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy: Complete Statistical AnalysisIndependent statistical analysis of Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01388777).
- Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CTS-1027 in Interferon-Naive Hepatitis C Patients: Complete Statistical AnalysisIndependent statistical analysis of CTS-1027 in Interferon-Naive Hepatitis C Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00925990).
- Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CURBIndependent statistical analysis of Cocaine Use Reduction With Buprenorphine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01402492).
- Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CUTEXIndependent statistical analysis of Cold Urticaria Treatment With Xolair: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01580592).
- CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer: Complete Statistical AnalysisIndependent statistical analysis of CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels: Complete Statistical AnalysisIndependent statistical analysis of Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01678313).
- Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis: Complete Statistical AnalysisIndependent statistical analysis of Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00001213).
- D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents: Complete Statistical AnalysisIndependent statistical analysis of D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01157429).
- D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder: Complete Statistical AnalysisIndependent statistical analysis of D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00864123).
- D-LUCSIndependent statistical analysis of Combined Pharmacotherapy for Cannabis Dependency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01020019).
- D-serine Augmentation of Neuroplasticity: Complete Statistical AnalysisIndependent statistical analysis of D-serine Augmentation of Neuroplasticity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03711500).
- Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites: Complete Statistical AnalysisIndependent statistical analysis of Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites: primary endpoint results, effect estimate with confidence interval,…
- Dacarbazine and Carmustine in Metastatic Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Dacarbazine and Carmustine in Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01692691).
- Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance: Complete Statistical AnalysisIndependent statistical analysis of Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung: Complete Statistical AnalysisIndependent statistical analysis of Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV: Complete Statistical AnalysisIndependent statistical analysis of Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02048722).
- DAISYIndependent statistical analysis of A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- DAR-PIAIndependent statistical analysis of DAR-901 TB Booster Vaccine to Prevent TB in Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02712424).
- Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab: Complete Statistical AnalysisIndependent statistical analysis of Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00504153).
- Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00423735).
- Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis: Complete Statistical AnalysisIndependent statistical analysis of DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03825315).
- DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway: Complete Statistical AnalysisIndependent statistical analysis of DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00903760).
- Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00382200).
- Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS: Complete Statistical AnalysisIndependent statistical analysis of Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…